(Q44704645)

5 December 2017

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers (English)

1 reference

5 December 2017

1 reference

Paul D Martin

1

1 reference

5 December 2017

Mike J Warwick

2

1 reference

5 December 2017

Aaron L Dane

3

1 reference

5 December 2017

Steve J Hill

4

1 reference

5 December 2017

Petrina B Giles

5

1 reference

5 December 2017

Paul J Phillips

6

1 reference

5 December 2017

Eva Lenz

7

1 reference

5 December 2017

1 November 2003

1 reference

5 December 2017

Clinical Therapeutics

1 reference

5 December 2017

25

1 reference

5 December 2017

2822-2835

1 reference

5 December 2017

11

1 reference

Optimizing the pharmacology of statins: characteristics of rosuvastatin

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

The effect of fluconazole on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Effect of itraconazole on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

The effect of erythromycin on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980336-3

7 January 2021

10.1016/S0149-2918(03)80336-3

Identifiers

DOI

1 reference

5 December 2017

1 reference